CA-CYGNVS-INC.
24.1.2023 14:01:50 CET | Business Wire | Press release
CYGNVS Inc. today emerged from stealth backed by $55 million in series A funding and unveiled its pioneering guided cyber crisis platform purpose-built to empower organizations to stay Connected, Confident, in Control and Compliant as they prepare for and respond to any cyber crisis.
“No matter how much is spent on cybersecurity, cyber crises are inevitable and every organization in the world needs to prepare and plan for that eventuality,” said Marc Goodman, global security advisor and The New York Times bestselling author of “Future Crimes.” “Successful response is surprisingly complex, and most victims fail because they try to cobble together their response at that time. Being prepared and having a practiced plan is critical to any organization’s cyber resilience."
When a cyber crisis does occur, preparation and practice can make a big difference. From data in The Cost of Data Breach Report 2022, organizations that are better prepared and practiced save an average of $1.38 million in direct costs.
CYGNVS (an acronym of CYber GuidaNce Virtual Space) empowers organizations to reduce their risk before a cyber crisis through preparation and practice and then reduce cost and impact of a cyber crisis with a guided, accelerated response.
Partnering With Insurance
Just as the insurance industry helped drive adoption of building sprinkler systems, which greatly reduced fire risk, the cyber insurance industry has deep expertise in cyber crisis preparation and response.
CYGNVS has partnered with AIG, a leading worldwide provider of cyber insurance. After responding to thousands of cyber breaches, AIG identified various critical challenges to optimize breach response, such as a client’s visibility into the entire end-to-end response process, secure post-event communications, and working effectively and consistently with external response providers including breach counsel and forensic consultants. AIG helped CYGNVS develop the requirements by providing guidance based on AIG’s experience, expertise and thought leadership in cyber claim resolutions, enabling CYGNVS to develop a robust platform to address the problems of organizations worldwide.
Today, CYGNVS insurance customers together represent half the cyber insurance market and CYGNVS is being rolled out to clients by leading insurers and brokers complementing their cyber insurance policies.
Back To Business, Faster
With CYGNVS, organizations can quickly assemble everyone contributing to the cyber crisis response in a safe, secure environment out of bank from internal channels. The platform converts static breach response plans into interactive and actionable processes and checklists. Internal teams and outside experts can be assigned roles and responsibilities, tasks are communicated in a digestible fashion and plans and workstreams can be easily and quickly updated as people, assets, regulations and threats change.
“CYGNVS was founded with the mission of making the world’s organizations lower their cyber risk by addressing the critical areas of preparation and response. We purpose-built CYGNVS as a guided cyber crisis platform to empower organizations to be Connected, Confident, in Control and Compliant before, during, and after a cyber crisis,” said Arvind Parthasarathi, Founder and CEO of CYGNVS.
CONNECTED
- Out-of-band, Secure, Mobile
- Accessible Anytime, Anywhere – mobile apps for iOS/Android and all browsers
- Pre-setup, Pre-configured and Ready-to-go
- Rapidly assemble team, assign roles, and initiate response
CONFIDENT
- Pre-built playbooks and Industry Templates
- Rapidly plug in ecosystem of already onboarded external experts like lawyers, forensics, insurance
- Practice and Simulate to build muscle memory
- Guided workflow supports new or inexperienced team members
CONTROL
- Guided, step-by-step, response execution
- Single Unified Command Center
- Visibility, Tracking, Alerts across Workstreams
- Ensure all required steps are performed with no missteps
COMPLIANT
- Fine grained access control across internal and external teams
- Help maintain privilege by managing information access
- Audit trail of documented evidence
- Simplify reporting to Regulators, Customers, and other stakeholders
CYGNVS is SOC2 Type 2 certified and ISO 27001 compliant and has been built from the ground up with industry-leading security standards, including multi-factor authentication (MFA), encrypting all data in transit and at rest, and separation and isolation best practices.
$55 million Series A Funding Round
Led by Andreessen Horowitz, with participation from Stone Point Ventures and EOS Venture Partners, CYGNVS will use the series A funding to further enhance the platform while expanding sales operations.
"Traditional multi-tenant cloud architectures don't work for the complex access and security challenges in a cyber crisis preparation and response," said Angela Strange, General Partner, Andreessen Horowitz. "The experienced cloud and security team at CYGNVS has built a robust end-to-end cyber crisis operating system from the ground up for successful crisis preparation and response."
Available Today
CYGNVS is now generally available across all segments and offered in English, French, Spanish, German, and Japanese. CYGNVS can be purchased direct or accessed as a no-cost benefit of cyber insurance policies from leading insurers and brokers. To learn more or schedule a demo, visit www.CYGNVS.com.
About CYGNVS Inc.
CYGNVS is a guided cyber crisis response platform purpose-built to empower organizations to be Connected, Confident, in Control and Compliant before, during and after a cyber crisis. Backed by a $55 million series A round from Andreessen Horowitz, Stone Point Ventures, and EOS Venture Partners, CYGNVS is headquartered in Silicon Valley, with offices in Canada, India, and Ireland. For more information, visit www.CYGNVS.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
